<DOC>
	<DOCNO>NCT00004928</DOCNO>
	<brief_summary>RATIONALE : Calcitriol may help prostate cancer cell develop normal cell . Zoledronate may delay prevent formation bone metastasis . Combining calcitriol zoledronate may effective treatment progressive prostate cancer . PURPOSE : Phase I trial study effectiveness combine calcitriol zoledronate treat patient progressive prostate cancer .</brief_summary>
	<brief_title>Calcitriol Zoledronate Treating Patients With Progressive Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose calcitriol administer zoledronate patient progressive prostate cancer . - Assess effect regimen calcium homeostasis bone turnover patient population . - Assess change PSA patient treat regimen . - Determine antitumor effect regimen patient . OUTLINE : This dose-escalation study calcitriol . Patients receive oral calcitriol weekly 3 consecutive day zoledronate IV monthly . Treatment continue absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos calcitriol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 3 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 30 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prior localize adenocarcinoma prostate undergone definitive radiation surgery demonstrate progression biochemically follow : Baseline PSA least 4 ng/mL At least 50 % increase PSA least 3 determination take 2 week interval No radiographically evident disease Neoadjuvant hormonal therapy prior radical prostatectomy radiotherapy allow Treatment intermittent approach allow therapy least 12 week OR Histologically confirm androgenindependent adenocarcinoma prostate following : Progression primary hormonal treatment ( e.g. , orchiectomy , estrogen therapy , gonadotropinreleasing hormone analog without antiandrogen ) either new osseous lesion bone , great 25 % increase bidimensionally measurable tumor mass , rise PSA value ( rise PSA 3 determination take least weekly interval , great 50 % baseline PSA ) despite castrate level testosterone ( great 30 ng/mL ) If receive antiandrogen part primary hormonal therapy , must meet criterion progression discontinuation antiandrogen No change hormonal therapy ( include prednisone dexamethasone ) within past 2 week If prior surgical orchiectomy , must continue medical therapy maintain castrate level testosterone Prior chemotherapy , palliative radiotherapy , radioisotope treatment allow PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 3 month Hematopoietic : WBC least 3,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL OR SGOT le 3 time upper limit normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance least 60 mL/min No history nephrolithiasis Must 2 function kidney Cardiovascular : No New York Heart Association class III IV heart disease Pulmonary : No severe debilitate pulmonary disease Metabolic : No preexist endocrine metabolic disorder impact calcium regulatory axis include hypercalcemia ( ionized serum calcium great 5.3 mg/dL total calcium great 10.5 mg/dL ) hypercalciuria ( great 300 mg urinary calcium/24 hour ) Other : No active secondary malignancy except nonmelanoma skin cancer Must maintain low calcium diet ( le 800 mg calcium daily ) No uncontrolled serious active infection No history malabsorption disorder No history inflammatory bowel disease PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : See Disease Characteristics Recovered prior endocrine therapy Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No concurrent radiotherapy sole measurable lesion Surgery : See Disease Characteristics Recovered prior surgery No concurrent surgery sole measurable lesion Other : No concurrent cholecalciferol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>